Not ideal, but at least they;re being honest and upfront about it.
...and it doesn't appear to be PYC's tech that was the failing point, but the drug being delivered that didn't meet its end point of efficacy.
Ann: Conclusion of Genentech Antimicrobial Collaboration, page-2
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
14.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $676.5M | |||
| Open | High | Low | Value | Volume |
| 14.0¢ | 14.5¢ | 13.5¢ | $687.7K | 4.887M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 87494 | 14.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.0¢ | 2187900 | 13 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| PYC (ASX) Chart |